Neurotensin receptor 1 (NTSR1) is overexpressed in several aggressive solid tumors, including colorectal and pancreatic cancer, making it a promising therapeutic target. SKL-35501 is a novel 225Ac-labeled radiopharmaceutical developed by SK Biopharmaceuticals Co. Ltd. that targets NTSR1 for α-particle therapy.